Evidence map›Paper›PMID 41708156›Full record

Observational studyRMD open2026

Colchicine resistance prediction criteria from the TURPAID cohort do not apply to the JIR cohort: a multicentre descriptive analysis.

Philippe Mertz, Inès Elhani, Isabelle Koné-Paut, Diana Dan, Sandrine Roque, Katerina Theodoropoulou, Jana Pachlopnick Schmid, Brigitte Bader-Menier, Alexandre Belot, Cécile Dumaine and 4 more

Abstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in RMD open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Philippe MertzDepartment of Internal Medicine, Sorbonne University, DMU3ID, ERN RITA, Hôpital Tenon, University, Assistance publique-hôpitaux de Paris (AP-HP), 4 rue de la Chine, 75020 Paris, France philippe.mertz2@gmail.com.ORCID 0000-0002-9781-7388
Inès ElhaniDepartment of Internal Medicine, Sorbonne University, DMU3ID, ERN RITA, Hôpital Tenon, University, Assistance publique-hôpitaux de Paris (AP-HP), 4 rue de la Chine, 75020 Paris, France.ORCID 0000-0002-9767-2262
Isabelle Koné-PautCentre de référence des maladies autoinflammatoires et de l'amylose (CEREMAIA), Paris, Île-de-France, France.ORCID 0000-0001-8939-5763
Diana DanRheumatology Department, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Sandrine RoqueService de médecine interne, CHU Nord, APHM, Marseille, France.
Katerina TheodoropoulouPaediatric Rheumatology and Immunology Unit, Department of Pediatrics, University Hospital of Lausanne (CHUV) and University of Lausanne (UNIL), Lausanne, Switzerland.
Jana Pachlopnick SchmidDivision of Immunology and Children's Research Center, University Children's Hospital, Zurich, Switzerland.
Brigitte Bader-MenierDepartment of Pediatric Immunology, Hematology and Rheumatology, Necker Hospital, AP-HP, National Reference Centre for Rheumatic and Autoimmune Diseases in Children, RAISE, Paris, Île-de-France, France.
Alexandre BelotNational Referee Centre for Pediatric-Onset Rheumatism and Autoimmune Diseases, Hospices Civils de Lyon, Pediatric Nephrology, Rheumatology, Dermatology Unit, Mother and Children University Hospital, Lyon, France.ORCID 0000-0003-4902-5332
Cécile DumaineGeneral Paediatrics, Department of Infectious Disease and Internal Medicine, Robert Debré Mother-Child University Hospital, Reference Centre for Rheumatic, AutoImmune and Systemic Diseases in Children (RAISE), AP-HP, Paris, France.
Charlotte Kevorkian-VerguetDepartment of General Pediatrics, Grenoble Alpes University Hospital, Grenoble, France.
Sébastien CavelotCentre de référence des maladies autoinflammatoires et de l'amylose (CEREMAIA), Paris, Île-de-France, France.
Sophie Georgin-LavialleDepartment of Internal Medicine, Sorbonne University, DMU3ID, ERN RITA, Hôpital Tenon, University, Assistance publique-hôpitaux de Paris (AP-HP), 4 rue de la Chine, 75020 Paris, France.ORCID 0000-0001-6668-8854
Véronique HentgenCentre de référence des maladies autoinflammatoires et de l'amylose (CEREMAIA), Paris, Île-de-France, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionFamilial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease. Colchicine is the first-line treatment, yet 5-10% of patients are resistant, increasing the risk of complications like amyloidosis. In 2023, Batu

methodsWe retrospectively analysed 236 genetically confirmed FMF patients treated with colchicine for ≥6 months. Patients were classified as colchicine-sensitive (CoS) or colchicine-resistant (CoR)

resultsA TURPAID score ≥2 was observed in 89% of paediatric and 76% of adult CoS patients. Mean scores were significantly higher in paediatric-onset FMF. ROC analysis showed poor discrimination in both paediatric and adult groups (area under the curve=0.6). Clinical features and attack patterns varied by age. The genetic component (1.5 points for

conclusionThe TURPAID score did not effectively predict colchicine resistance in the JIR cohort. Its limited generalisability may stem from age-related differences, recall bias and excessive genetic weighting. Genetic results should be a prerequisite and not a determinant of colchicine resistance prediction scores in FMF.

Indexed as

ColchicineDrug ResistanceFamilial Mediterranean FeverAdolescentAdultChildChild, PreschoolFemaleHumansMaleMutationPyrinRetrospective StudiesROC CurveTurkeyYoung AdultColchicinePyrinAmyloidosisFamilial Mediterranean FeverHereditary Autoinflammatory DiseasesTherapeutics

Identifiers

PMID41708156
PMCPMC12918656

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.